Cargando…
Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases
Tissue fibrosis is a key factor leading to disability and death worldwide; however, thus far, there are no approved treatments for fibrosis. Transforming growth factor (TGF)-β is a major pro-fibrotic cytokine, which is expected to become a target in the treatment of fibrosis; however, since TGF-β ha...
Autores principales: | Shi, Ning, Wang, Zhihong, Zhu, Hecheng, Liu, Weidong, Zhao, Ming, Jiang, Xingjun, Zhao, Jin, Ren, Caiping, Zhang, Yan, Luo, Longlong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197809/ https://www.ncbi.nlm.nih.gov/pubmed/35147920 http://dx.doi.org/10.1007/s12026-022-09267-y |
Ejemplares similares
-
The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas
por: Yan, Xuejun, et al.
Publicado: (2021) -
FBXW7 and the Hallmarks of Cancer: Underlying Mechanisms and Prospective Strategies
por: Shen, Wenyue, et al.
Publicado: (2022) -
Apilimod alters TGFβ signaling pathway and prevents cardiac fibrotic remodeling
por: Cinato, Mathieu, et al.
Publicado: (2021) -
Crucial roles of different RNA-binding hnRNP proteins in Stem Cells
por: Xie, Wen, et al.
Publicado: (2021) -
ESRG is critical to maintain the cell survival and self-renewal/pluripotency of hPSCs by collaborating with MCM2 to suppress p53 pathway
por: Li, Shasha, et al.
Publicado: (2023)